Under new leadership, Triangle biotech Aerami Theraputics seeks big investments

This funding represents the company's first debt and security raise. Since the company's first raise in 2015, all funding to date has been equity only, totaling more than $86 million, according to SEC filings.

Related Keywords

Joshua Ziel ,Anne Whitaker ,Lisa Ya , ,Aerami Therapeutics ,Chief Operating Officer Joshua Ziel ,Chairwoman Anne Whitaker ,